Skip to content
Brilliant Blue Biosciences logoBrilliant BlueBiosciences
← Research & Industry News
External source

Semiautomated platform delivers consistent batches of extracellular vesicles for potential regenerative therapies

A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Blood and Tissue Bank (BST) has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step toward their clinical application.

Published by
Phys.org
Evidence type
Laboratory

A study led by researchers from the Germans Trias i Pujol Research Institute (IGTP) and the Blood and Tissue Bank (BST) has developed and validated a manufacturing platform for extracellular vesicles that meets pharmaceutical quality requirements, marking a key step toward their clinical application.

This item was selected automatically by our daily literature and news monitor because it matches the topics we follow. Read the full story at Phys.org.

Drug Delivery & Nanomedicine

Let's engineer the next delivery breakthrough together

We co-develop nanocarrier and biosensing programmes with pharma, biotech and academic groups — from target selection through scale-up.

ResearchersRequest a technical consultationTalk formulation, characterisation or assay design with one of our scientists.Industry partnersExplore co-developmentFeasibility studies, co-development programmes and licensing.InvestorsExplore the market opportunitySourced market sizes, pipeline, investment and deal data for genetic medicine delivery.
Semiautomated platform delivers consistent batches of extracellular vesicles for potential regenerative therapies | Brilliant Blue Biosciences